Ten post jest także dostępny w języku: polski
Biomed Lublin has completed the process of isolating immunoglobulin against Sars-CoV-2 from the recovered plasma. Today, the company will carry out the process of aseptic filling of the preparation into ampoules. Does this mean that Poland already has a drug for COVID-19?
Drug has to undergo many tests…
Biomed Lublin is working hard on the production of immunoglobulin, which is to be an effective agent in the treatment of COVID-19. The first contracts for the supply of the plasma containing anti-SARS-CoV-2 antibodies were signed by the company at the end of July, which we have written about in more detail here.
After being placed in ampoules, the drug will undergo qualitative tests, including product stability tests. Afterwards, immunoglobulin will be tested in four centres in Poland, including: Lublin, Bytom, Bialystok and Warsaw, according to the approved research protocol. As stated in the report, the drug for COVID-19, of which Biomed Lublin is the supplier, will be submitted for non-commercial clinical trials probably in the fourth quarter of 2020.
…and the number of COVID-19 cases is not falling
Work on an effective method to combat COVID-19 is ongoing around the world. Both vaccines and medicines are being developed to support the treatment process itself. However, the autumn wave of the disease is getting closer and closer, and the number of cases of COVID-19 is increasing.
As of 22 September (morning report), the number of samples tested in Poland for coronavirus COVID-19 infection was nearly 3.2 million, according to official data presented by the Ministry of Health. The data include molecular tests performed by laboratories on the list of the Ministry of Health. It is worth noting that the number of diagnosed infected people in Poland has almost doubled over the course of two months, to 80,699 people, of whom nearly 3% have died and over 80% have recovered.